hVIVO plc (LON:HVO – Get Free Report) shares dropped 6.8% during mid-day trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.26).
hVIVO Trading Down 6.8 %
The firm has a market cap of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a 50-day moving average price of GBX 23.58 and a 200 day moving average price of GBX 26.77.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
- Five stocks we like better than hVIVO
- What is a Stock Market Index and How Do You Use Them?
- 3 Legacy Tech Companies Reemerging as AI Leaders
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- How to Most Effectively Use the MarketBeat Earnings Screener
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
